Pancreatic Cancer News & Features

Genetic culprit in pancreatic cancer risk identified

Delicia Honen Yard January 17, 2012

Mutations in the ATM gene may raise a person's hereditary risk for pancreatic cancer, information that could lead to better screening methods for the disease.
 

ACS annual report says cancer mortality is decreasing

Delicia Honen Yard January 10, 2012

Cancer incidence rates in men declined by 0.6% per year and remained stable in women and cancer mortality fell by 1.8% per year for men and by 1.6% per year for women between 2004 and 2008.
 

Gene Involved in Familial Pancreatic Cancer Identified

January 04, 2012

Specific mutations in the ATM gene increase the hereditary risk of familial pancreatic cancer.
 

How would I know if I may have pancreatic cancer?

December 20, 2011

More than 44,000 cases of cancer of the pancreas will be diagnosed in 2011, estimates the NCI. This article, suitable for patients, reviews the symptoms, diagnosis, and treatment of pancreatic cancer.
 

Everolimus combination improved progression-free survival in neuroendocrine tumors

Delicia Honen Yard December 14, 2011

Progression-free survival improved in patients with advanced neuroendocrine tumors when everolimus rather than placebo was used in combination with octreotide long-acting repeatable.
 

Diabetes drug helps prevent growth of breast cancer cells

Delicia Honen Yard December 09, 2011

Metformin, a widely used agent in the treatment of type 2 diabetes, stopped a number of natural and man-made chemicals from stimulating the growth of breast cancer cells.
 

Oxygen generators help kill tumors from within

October 18, 2011

An electronic device that can be implanted in a tumor uses the energy from ultrasound signals to generate oxygen, boosting the effectiveness of radiation and chemotherapy.
 

Costly clots common in cancer

Delicia Honen Yard October 18, 2011

As many as 1 in 5 people risk developing a venous thromboembolism (VTE) within a year after undergoing treatment for some types of cancers, researchers reported.
 

New screening protocol for pancreatic cancer is better than standard means

Delicia Honen Yard August 09, 2011

Using the CA 19-9 tumor marker followed by an endoscopic ultrasound is more likely to detect stage 1 pancreatic cancer in persons at high risk for the disease than is using CA 19-9 alone.
 

New treatments for pancreatic cancer

June 01, 2011

FOLFIRINOX was more effective than gemcitabine in increasing survival and delaying disease progression in metastatic pancreatic cancer, plus new indications for everolimus and sunitinib.
 

Pancreatic Cancer Clinical Trials

Clinical Trial: Vaccine Therapy With or Without Cyclophosphamide in Treating Patients Undergoing Chemotherapy and Radiation Therapy for Stage I or Stage II Pancreatic Cancer That Can Be Removed by Surgery

Clinical Trial: Early Increase in Blood Flow (EIBS) in the Duodenum in Patients With Pancreatic Cancer

Clinical Trial: Stool Testing for Pancreatic Cancer

Clinical Trial: Computer Tools for Improving Early Diagnosis and Treatment in Healthy Volunteers or Patients With Pancreatic Cancer or Who Are At Risk For Pancreatic Cancer or Who Have a Noncancer Pancreatic Disorder

Clinical Trial: A Pilot Study, Evaluating the Efficacy of Regulatory T-cell Suppression by Ontak in Metastatic Pancreatic Cancer

Free CE from mycme.com

Discussions on Emerging Concepts and Controversies in the Treatment of Patients with Advanced Non-Small Cell Lung Cancer

2.00 / AMA PRA Category 1 Credit(s)TM
This program reviews developments in maintenance therapy and evaluates the relevance of tumor histology and biomarker analysis for the management of NSCLC patients.
 

Cancer care is expensive.
CancerCare can help.


Connect Booklets
 Subscribe to the RSS for this page  [view all our RSS feeds here]

Web Exclusives

Psychosocial approach useful in managing cancer pain

February 03, 2012

Psychosocial interventions, including skills instruction and education, can help reduce pain in persons with cancer, confirm the results of a recent meta-analysis.
 

Experimental agent slows progression of colorectal cancer

February 02, 2012

The investigational drug regorafenib conferred a statistically significant survival benefit in patients with metastatic colorectal cancer in whom no standard therapy was effective.
 

In HER2 breast cancer, lapatinib works better with trastuzumab than without

February 01, 2012

Lapatinib is not as effective as trastuzumab against (HER2)-positive breast cancer, but combining the two nearly doubles the effectiveness seen with either one alone.
 

This material may not be published, broadcast, rewritten or redistributed in any form without prior authorization.

Your use of this website constitutes acceptance of Haymarket Media's Privacy Policy and Terms & Conditions